S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
NASDAQ:ACOR

Acorda Therapeutics - ACOR Price Target & Analyst Ratings

$0.47
+0.01 (+2.18%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.45
$0.48
50-Day Range
$0.31
$0.64
52-Week Range
$0.28
$4.99
Volume
97,025 shs
Average Volume
259,681 shs
Market Capitalization
$6.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Acorda Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

N/A
Based on 0 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
8/13/21 to 8/13/22
1 Month Ago
7/14/21 to 7/14/22
3 Months Ago
5/15/21 to 5/15/22
1 Year Ago
8/13/20 to 8/13/21
Consensus RatingN/A
Buy
Buy
Buy
Strong Buy N/A
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy N/A
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold N/A
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell N/A
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/A$10.00$10.00$22.50
Predicted UpsideN/A156.41% Upside156.41% Upside367.13% Upside
Get Acorda Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.


ACOR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Acorda Therapeutics Stock vs. The Competition

TypeAcorda TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
0.00
2.71
2.50
Consensus RatingN/ABuyHold
Predicted Upside723.74% Upside13.81% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
433
59.48%
Underperform Votes
295
40.52%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/27/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$10.00+156.41%
1/13/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$5.00 ➝ $35.00+426.32%
8/11/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$6.00+35.10%
2/16/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell
(Data available from 8/13/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ACOR Price Target - Frequently Asked Questions

Do MarketBeat users like Acorda Therapeutics more than its competitors?

MarketBeat users like Acorda Therapeutics less than other Medical companies. 59.48% of MarketBeat users gave Acorda Therapeutics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.


Stock Ratings Reports and Tools

This page (NASDAQ:ACOR) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.